Jasuja Guneet K, Bhasin Shalender, Rose Adam J, Reisman Joel I, Skolnik Avy, Berlowitz Dan R, Gifford Allen L
a Center for Healthcare Organization and Implementation Research (CHOIR) , ENRM VAMC , Bedford , MA , USA.
c Department of Health Law, Policy and Management , Boston University School of Public Health , Boston , MA , USA.
AIDS Care. 2018 Oct;30(10):1207-1214. doi: 10.1080/09540121.2018.1447080. Epub 2018 Mar 19.
Testosterone supplementation has been widely used in those infected with human immunodeficiency virus (HIV) for hypogonadism, and wasting. But with effective antiretroviral therapy and increasing recognition of atherosclerotic disease and adults infected with HIV, the risks of inappropriate testosterone use in HIV-infected patients are far better recognized than previously. Testosterone use has expanded among U.S. males, but few studies have examined prescribing in those infected with HIV. In a national cohort of males with at least one outpatient prescription in the Veterans Health Administration (VHA), we examined 9475 HIV-infected males, including 2484 who had received testosterone and a randomly selected 6991 who had not. For comparison, we identified 1,387,241 uninfected males (189,369 had received testosterone and a randomly selected 1,197,872 had not). We determined rates of new and prevalent testosterone use, and also examined the adequacy of the diagnostic evaluation that had preceded testosterone initiation among our HIV-infected and uninfected testosterone groups. Our main results were as follows. HIV-infected men had higher rates of initiation (0.8% vs. 0.4% in FY09; p < 0.001) and prevalence of testosterone use (2.2% vs. 0.8% in FY08; p < 0.001) compared to the uninfected men across the entire period. Trends of prescribing for both groups followed a similar pattern, rising from FY08, reaching a peak in FY13, and then dipping in FY 14. Only 1.1% of HIV-infected patients had a fully guideline-concordant workup before starting testosterone therapy, compared to 3.5% of uninfected patients (p < 0.001). In conclusion, testosterone use among HIV-infected patients in the VHA system rose to a peak in FY13 and has decreased somewhat since. Only a small minority of HIV-infected patients who receive testosterone therapy from VHA have undergone an appropriate workup before starting therapy, suggesting an opportunity for improvement.
睾酮补充疗法已广泛用于感染人类免疫缺陷病毒(HIV)且患有性腺功能减退和消瘦的患者。但随着有效的抗逆转录病毒疗法的出现以及对动脉粥样硬化疾病的认识增加,HIV感染成年人中不恰当使用睾酮的风险比以前得到了更充分的认识。睾酮在美国男性中的使用有所增加,但很少有研究调查HIV感染者的处方情况。在退伍军人健康管理局(VHA)至少有一张门诊处方的全国男性队列中,我们研究了9475名HIV感染男性,其中2484人接受过睾酮治疗,随机抽取6991人未接受过睾酮治疗。为作比较,我们确定了1387241名未感染男性(189369人接受过睾酮治疗,随机抽取1197872人未接受过睾酮治疗)。我们确定了新使用和正在使用睾酮的比率,并检查了在HIV感染组和未感染睾酮组中开始使用睾酮之前诊断评估的充分性。我们的主要结果如下。在整个时期内,与未感染男性相比,HIV感染男性开始使用睾酮的比率更高(2009财年为0.8%对0.4%;p<0.001),且正在使用睾酮疗法的比例也更高(2008财年为2.2%对0.8%;p<0.001)。两组处方趋势遵循相似模式,从2008财年开始上升到2013财年达到峰值,然后在2014财年下降。只有1.1%的HIV感染患者在开始睾酮治疗前进行了完全符合指南要求的检查,相比之下,未感染患者这一比例为3.5%(p<0.001)。总之,VHA系统中HIV感染患者使用睾酮的情况在2013财年达到峰值,此后有所下降。从VHA接受睾酮治疗的HIV感染患者中只有一小部分在开始治疗前接受了适当的检查,这表明有改进的空间。